Tributary Capital Management, LLC Sage Therapeutics, Inc. Transaction History

Tributary Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 19, 2022	SELL	$27.52 - $37.99 $544,896 - $752,202	-19,800 Closed	0 $0
Q1 2022 Apr 22, 2022	BUY	$30.71 - $45.71 $9,213 - $13,713	300 Added 1.54%	19,800 $655,000
Q4 2021 Jan 06, 2022	BUY	$37.06 - $47.11 $352,070 - $447,545	9,500 Added 95.0%	19,500 $830,000
Q3 2021 Oct 14, 2021	BUY	$40.26 - $57.37 $402,600 - $573,700	10,000 New	10,000 $443,000
Q2 2021 Jul 15, 2021	SELL	$54.88 - $79.29 $839,664 - $1.21 Million	-15,300 Closed	0 $0

Q1 2021 Apr 20, 2021	BUY	$70.65 - $96.76 $1.08 Million - $1.48 Million	15,300 New	15,300 $1.15 Million

220

52.7M

207K

191K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $730M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Tributary Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Tributary Capital Management, LLC with notifications on news.